Lv42
510 积分 2023-04-19 加入
Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study
7小时前
待确认
Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study
7小时前
待确认
Innovative, early-phase clinical trials of drug–radiotherapy combinations
12天前
已完结
MA11.04 First-in-Class PD-1/IL-2 Bispecific Antibody IBI363 In Patients with Advanced Non-Small Cell Lung Cancer in a Phase I Study
20天前
已完结
MA11.12 A Phase Ib Study of TQB2618 (Anti-TIM-3) in Combination with Penpulimab and Chemotherapy in Patients with Non-Small Cell Lung Cancer
28天前
已完结
Adoptive cell therapy for solid tumors beyond CAR-T: Current challenges and emerging therapeutic advances
30天前
已完结
CAR T cell combination therapies to treat cancer
30天前
已完结
A systematic review of antibody-drug conjugates and bispecific antibodies in head and neck squamous cell carcinoma and nasopharyngeal carcinoma: Charting the course of future therapies
1个月前
已完结
Treating Head and Neck Cancer in the Age of Immunotherapy: A 2023 Update
1个月前
已完结
BL-B01D1, a first-in-class EGFR–HER3 bispecific antibody–drug conjugate, in patients with locally advanced or metastatic solid tumours: a first-in-human, open-label, multicentre, phase 1 study
1个月前
已完结
皖公网安备34019202002308
